AI-driven drug discovery company Recursion Pharmaceuticals announced a 20% workforce reduction following strategic pipeline pruning and funding constraints faced amid biotech capital market turbulence. The restructuring includes deprioritizing multiple clinical programs and is expected to extend cash runway through 2027. This development highlights challenges confronting AI-biotech integration and industry funding volatility.